Cover Image


Global Biobanks Market - Segmented by Equipment, Media, Service, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 546540
出版日期 內容資訊 英文 102 Pages
商品交期: 最快1-2個工作天內
Back to Top
藥物研發及再生醫療的生物銀行的全球市場 Global Biobanks Market - Segmented by Equipment, Media, Service, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2018年04月01日 內容資訊: 英文 102 Pages


第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
    • 簡介
  • 市場的推動要素
    • 政府及NGO的出資
    • 慢性疾病的盛行率上升
    • 再生醫療的進步
    • 藥物研發及藥品開發的發展
  • 市場阻礙因素
    • 法規上的課題
    • 保存設施的問題
    • 高成本

第4章 市場區隔:各應用領域

  • 藥物研發
  • 樣品收集、銷售信息
  • 再生醫療

第5章 市場區隔:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 韓國
  • 其他地區
    • 巴西

第6章 競爭情形

  • 簡介
  • 收購、合併
  • 產業擴大
  • 新產品的投入

第7章 企業簡介

  • Core Dynamic Ltd
  • Atlanta Biologicals
  • Biolife Solutions
  • Bioniche Pharma USA Lc
  • Cell & Tissue Systems LLC
  • Essential Pharmaceuticals
  • Lifeline Scientific Inc
  • Genzyme Corporation
  • Preservation Solution
  • Sigma Aldrich Corporation
  • Teva Pharmaceutical Industries Ltd

第8章 附錄


Product Code: 49822

The global biobanks market is expected to register a CAGR of 6% during the forecast period of 2018-2023. Biobanks are the biorepository where various biomaterials are stored for research purposes. A few decades ago, biobanks were primarily restricted to established economies carrying out breakthrough research in biological sciences. The biobank industry has come a long way since then, with an increasing number of biobanking services and global presence.

Advancements in Stem Cell and Regenerative Medicine Research

Research in regenerative medicine is becoming more intense and advanced in the developed countries, especially in the United States and Europe. These advancements in regenerative medicine show considerable potential for disease reversal. Stem cells can treat many hitherto untreatable diseases and are likely to be the therapeutic option for many diseases in the future. Its therapeutic application in the treatment of amyotrophic lateral sclerosis (ALS), Alzheimer's disease, other autoimmune diseases, diabetes, musculoskeletal diseases, ocular diseases, rare genetic diseases, and cancer are being researched through clinical trials. Several of these studies have generated promising results. According to, currently, there are around 196 studies registered for research on regenerative medicine. The increasing popularity of regenerative medicine research is attracting substantial funding from both public and private investors. This rise in regenerative medicine research has also driven the demand for biobanks, which act as the reservoir for stem cells and other biological samples that are used in regenerative medicine research. The other factors, such as rising incidences of chronic diseases, advances in drug discovery, and R&D funding and investments by government and non-governmental organizations are driving the global biobanks market.

Regulatory Issues

Biobanks are under ethical oversight from independent reviewers, while the governance process is intended to be public. Oversight may come at the local level, or from an institutional review board, which includes research, particularly medical research. Specific institutional review boards enforce standards set by their respective country's government. As of now, many countries use laws modeled upon various biobank governance recommendations, which have been proposed internationally. However, there are no internationally accepted set of governance guidelines, which can be designed to work with biobanks. Many existing biobanks typically adapt to the recommendations of guidelines that are accepted for human-subject research and include newer ones, as they are added to the existing guidelines.

The idea of establishing a powerful national population blood-based resource for researchers was first proposed in 1999. Since then, many detailed protocols, ethics, and other government regulations have been developed, while subjecting biobanks to the very highest degree of scrutiny, consultation, and review. However, lack of parity in international sets of guidelines has led to regulatory issues in many countries.Some countries have strict regulatory guidelines, which would eventually hinder the growth of the global biobank market. Therefore, this lack of a defined set of regulations and guidelines, and the irregular regulatory frameworks among the underdeveloped and developing countries are restraining the expansion of the global biobank market. The other factor, such as cost constraints is also hindering the market.

United States Leads the Market in North America

The United States biobanks market held the largest market share in 2017 in North America due to the presence of high-quality healthcare system. The biobanks market has recently started in the emerging nations, wherein major investments are expected to happen. In the Asia-Pacific sector, China and South Korea have been identified as potential emerging markets due to high R&D investments.

Key Developments in the Market:

January 2018: Bio-Techne acquired Atlanta Biologicals Inc.

August 2017: Thermo Fisher Scientific acquired the Patheon.


Reasons to Purchase the Report

Follow the current and future biobanks market outlook in the developed and emerging markets

Analyzing various perspectives of the market with the help of Porter's Five Forces Analysis.

Identify the segment that is expected to dominate the market.

Identify the regions that are expected to witness the fastest growth during the forecast period.

Identify the latest developments, market shares, and strategies employed by the major market players.

3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Products and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Drivers
    • 6.1.1 Advancements in Stem Cell and Regenerative Medicine Research
    • 6.1.2 Rising Incidences of Chronic Diseases
    • 6.1.3 Advances in Drug Discovery and Development
    • 6.1.4 R&D Funding and Investments by Government and Non-Governmental Organizations
  • 6.2 Restraints
    • 6.2.1 Regulatory Issues
    • 6.2.2 Cost Constraints
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Equipment
    • 7.1.1 Cryogenic Storage System
    • 7.1.2 Refrigerator
    • 7.1.3 Ice Machine
    • 7.1.4 Freezer
    • 7.1.5 Alarm Monitoring System
    • 7.1.6 Others
  • 7.2 By Media
    • 7.2.1 Optimized Media
    • 7.2.2 Non-Optimized Media
  • 7.3 By Service
    • 7.3.1 Human Tissue Biobanking
    • 7.3.2 Stem Cell Biobanking
    • 7.3.3 Cord Banking
    • 7.3.4 DNA/RNA Biobanking
    • 7.3.5 Others
  • 7.4 By Application
    • 7.4.1 Regenerative Medicine
    • 7.4.2 Drug Discovery
    • 7.4.3 Disease Research
  • 7.5 By Geography
    • 7.5.1 North America
      • United States
      • Canada
      • Mexico
    • 7.5.2 Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
      • Rest of Europe
    • 7.5.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia & New Zealand
      • South Korea
      • Rest of Asia-Pacific
    • 7.5.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of the Middle East & Africa
    • 7.5.5 South America
      • Brazil
      • Argentina
      • Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Atlanta Biologicals, Inc. (Bio-Techne)
  • 9.2 Biolife Solutions, Inc.
  • 9.3 Essential Pharmaceuticals, LLC
  • 9.4 Hamilton Company
  • 9.5 Lonza Group Limited
  • 9.6 Preservation Solutions, Inc.
  • 9.7 Sigma Aldrich Corporation
  • 9.8 Stemcell Technologies, Inc.
  • 9.9 Thermo Fisher Scientific, Inc.

List Not Exhaustive

10. Future of the Market

11. Disclaimer

Back to Top